Our technology is currently being utilised to highlight our system’s versatility and potential to become the next generation’s immunohistochemistry (IHC) detection system in tissue diagnostics. Our involvement in these studies aims to showcase the range of different applications our technology can be used for. Each pilot study contributes to improving our understanding of the capability and flexibility of our technology, while also exploring new opportunities and applications in the field.

Ongoing Pilot Studies

Collaboration with a research group at Dalarnas Research Laboratory in Sweden


The study examines the compatibility of Lumito’s UCNP technology and previously established methods of analysis for breast cancer.

Collaboration with a research group at Uppsala University in Sweden


The study initially examines the refined capability of UCNP in detecting the biomarker PD-L1. 

Completed Pilot Studies

International pilot study in collaboration with a research group at University Hospitals Coventry and Warwickshire in the United Kingdom 


The study focused on detecting immunocomplex and complement deposition in renal biopsies using Lumito’s technology. 


The results will be presented in June at Liverpool Congress Pathology 2023 through a poster presentation. 

Collaboration with a research group at Umeå University in Sweden


The study explored the capacity of Lumito’s technology when quantifying signals compared to traditional DAB staining.


The study proved that Lumito’s technology offers more precise measurement results compared to traditional DAB staining, which saturates quickly and decreases the possibility of correct quantification. The research group in Umeå wrote an article about the study published in Cancer Immunology Research. See a presentation of the results here.

Contact us if you’re interested in using our technology in your research


A presentation about a study in pancreatic cancer using Lumito’s imaging technology